Earnings call transcript: Cadre Holdings Q1 2026 EPS Misses, Stock Slides

Cadre Holdings missed Q1 2026 EPS by 50% ($0.05 vs. $0.10) and revenue slightly missed at $155.4 million vs. $156.66 million, sending the stock down 4.92% after hours to $28.38 and 1.94% lower in premarket trading. Offseting the miss, net sales rose 19% year over year, backlog hit a record $355 million, and management reaffirmed full-year 2026 guidance for $736 million-$758 million of net sales and $136 million-$141 million of adjusted EBITDA. The call also highlighted ongoing M&A integration, including TYR Tactical and Alien Gear Holsters, plus supportive defense and nuclear budget trends.

Analysis

The market is treating this as a classic quality-guidance reset, but the more important signal is that operating leverage is still intact and likely being deferred, not destroyed. The combination of record backlog, backlog mix skewed to later-shipping items, and a full-quarter contribution from TYR sets up a mechanically stronger second half; that makes the near-term earnings miss less informative than the path of conversion over the next 2-3 quarters. The selloff also likely reflects disappointment that the quarter did not monetize the backlog as quickly as hoped, which creates a window for sentiment to overshoot fundamentals.

The bigger second-order issue is mix. If distribution softness is coming from discretionary third-party items while Cadre-made safety products remain resilient, then the business is silently upgrading its quality: lower-margin consumer/distribution revenue can fade while higher-conviction defense/public-safety orders carry the book. That is supportive for margins into late 2026, but it also means reported growth may remain choppy until the backlog converts, so the stock can stay technically weak despite improving underlying demand.

From a catalyst standpoint, the next inflection points are not macro but cadence: Q2 revenue guidance, sequential backlog burn, and evidence that TYR/Alien Gear contribute cross-sell rather than merely add scale. The nuclear budget shift is a medium-term tailwind for select segments, but the consensus is likely overestimating how quickly those dollars translate into P&L; the real upside is in 2027-2028 order flow, not this quarter. Contrarian take: the post-earnings drawdown likely discounts too much near-term margin noise and not enough backlog visibility, but if management fails to show margin expansion by Q2/Q3, the market will re-rate this as a capital-allocation story rather than a clean compounder.

Key Decisions for Investors

• Tactically buy CDRE on post-earnings weakness over the next 3-5 trading days; target a mean reversion trade toward the pre-print area if management commentary on backlog conversion remains stable. Risk/reward is attractive if the stock is pricing a permanent margin reset when the issue appears to be timing and mix.
• Structure a bullish call spread in CDRE for the next 2-3 quarters (e.g., 6-9 month tenor) to express recovery in the back-half EBITDA margin ramp. Stop thesis if Q2 print or July guidance update shows backlog failing to convert into revenue.
• Pair trade: long CDRE / short a lower-quality industrial or defense-adjacent distributor with more discretionary exposure. The trade works if investors rotate toward mission-critical revenue streams and away from businesses where demand softness is more cyclical.
• Avoid chasing the stock until management proves margin recovery in Q2; use any bounce to build rather than initiate size. If the next quarter still shows no sequential gross margin improvement, exit the long and treat backlog as a delayed rather than accretive catalyst.
• For broader thematic exposure, add a small long in NFTFF versus CDRE on a 6-12 month view if you want cleaner nuclear-budget torque. CDRE has more diversified growth, but NFTFF may be the higher-beta way to express the DOE weapons/reactors budget shift.